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Neuroblastoma (NBL) is the most common extra-
cranial solid malignancy of childhood, and has a broad
spectrum of clinical presentations and behavior.
Although low- and intermediate-risk NBL are mostly
curable [1,2], high-risk NBL has proven refractory to
conventional treatment modalities [3-5]. Despite the
unsatisfactory responses to conventional therapies,
some improvements in outcome have been achieved
through the escalation of therapeutic intensity [6].
Although even the most intense conventional therapy
results in long-term event-free survival (EFS) of
much\40%, improvements in EFS can be achieved
through the addition of consolidation therapy with
high-dose therapies that exceed marrow tolerance.INITIAL STUDIES
Investigators in the late 1980s and early 1990s
began exploring the hypothesis that increased treat-
ment intensity beyond marrow tolerance would
improve survival in patients with high-risk NBL. Mul-
tiple early single-arm or retrospective studies sug-
gested that autologous transplantation might indeed
improve the EFS of these patients, although none of
the studies were randomized and may have been
influenced by selection bias [7-12]. The largest
retrospective analysis was performed through the
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transplant studies mentioned below. A total of 1070
transplantations for high-risk NBL were analyzed,
and 2-year survival among the group of patients who
had reached a stem cell transplant (SCT) procedure
was 49%. Most relapses occurred within the first 18
months following transplantation, and there were no
survivors among the group of the 48 patients who
relapsed and underwent a second SCT. Notably,
late relapses were found as long as 7 years from
transplantation [13].RANDOMIZED TRIALS
The promise suggested by these early studies pro-
pelled prospective evaluation of autologous transplan-
tation for high-risk NBL. The largest of these was the
prospective randomized Children’s Cancer Group
phase III 3891 trial. In 3891, patients were randomized
to a consolidation regimen consisting of autologous
bone marrow transplantation versus continuation che-
motherapy. Following consolidation, patients were
then randomized to biologic therapy with 13-cis-reti-
noic acid (RA) versus no further therapy [4]. The study
found that those treated with high-dose chemotherapy
and transplantation had a significantly better EFS than
those treated with chemotherapy alone. The second
randomization demonstrated that treatment with RA
further improved the outcome among patients without
progressive disease.With an estimated 38%EFS 3.7 at
years from diagnosis in the best group, this study
helped establish autologous transplantation followed
by 6 months of oral RA therapy as the new standard
of care for these patients. Other studies of autologous
SCT in high-risk NBL have since built on the results
of 3891. The conditioning regimens used in these stud-
ies have varied, with the greatest difference being that
some studies have used total body irradiation (TBI)
in the conditioning regimen and others have not.
There have been no randomized trials of the use of
TBI during conditioning, and although it may improve
outcomes, it also results in significant late effects in this
young (median age 3) patient population. Overall,
these studies have led to the current core standard
for NBL treatment: 5 to 6 cycles of induction chemo-
therapy, surgery, radiotherapy (at a minimum to the
tumor bed), and SCT followed by oral RA. To this,
Table 1. Results from Selected Studies of Autologous SCT in High-Risk Neuroblastoma*
Group N Study Type EFS from EFS Myeloablative Regimen(s)
EBMT [13] 1070 Retrospective Transplant 49% (2-year) Various
Transplant 33% (5-year)
CCG 3891 [4] 539 Phase III Estimated from diagnosis 38% (3.7-year) CEM/TBI
Grupp et al. [3] 97 Phase II Diagnosis 55% (3-year) No. 1 CECtx
No. 2 Mel/TBI
Kletzel et al. [17] 25 Phase II Diagnosis 57% (3-year) No. 1 CE
No. 2 CE
No. 3 TCtx
Villablanca et al.† 73 Phase II Transplant 49% (3-year) CEM
Transplant 47% (5-year)
Kreissman et al. [25] 489 Phase III Diagnosis 49% (2-year) CEM
(489 randomized, 398 transplanted) Diagnosis 40% (3-year)
Transplant 46% (3-year)
Ladenstein et al. [20] 1577 Phase III Transplant 33% (3-year) CEM
(598 randomized) Transplant 49% (3-year) Bu/Mel
Table extensively adapted from Fish et al., Bone Marrow Transplantation (2008) 41, 159-165 [78].
C indicates carboplatin; Ctx, cyclophosphamide; E, etoposide; EBMT, European Group for Blood and Marrow Transplantation; M, Mel, melphalan;
T, thiotepa; TBI, total body irradiation.
*Study populations differed significantly in these 6 studies. The EBMTanalysis included allogeneic transplants and transplants after relapse. Villablanca
et al. included only stage 4 >1 year post-SCT in the group presented.
†Villablanca et al., unpublished data.
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cluding the anti-GD2 antibody 14.18, interleukin-2,
granulocyte macrophase-colony stimulating factor,
and RA) based on recent data from the Children’s
Oncology Group (COG) ANBL0032 study, which
showed a superior outcome in patients who received
this immunotherapy-based treatment [14].TANDEM TRANSPLANTATION
Given the evidence that dose-intensity correlates
with outcome, and that high-dose chemotherapy
with autologous stem cell rescue renders a statistically
significant improvement in survival, it was logical to
examine sequential courses of high-dose chemother-
apy with stem cell rescue, otherwise known as tandem
transplantation. Tandem transplantation allows for
even greater dose intensity in consolidation, with the
potential to introduce different active agents at each
transplantation. A very early attempt to employ this
technique was complicated by unacceptable
treatment-related mortality (TRM) [15]. Several
groups have retested the tandem transplantation
approach with more promising results [3,16,17].
The largest of these studies was conducted over 6
years at 4 cooperating institutions [3,16]. The study
was designed using early collection of peripheral blood
stem cells (PBSCs) and two sequential myeloablative
regimens containing distinct agents: (SCT#1)
carboplatin, etoposide, and cyclophosphamide,
followed by SCT#2 melphalan and TBI. TRM in
this study was 6% and included 2 patients who died
of Epstein-Barr virus lymphoproliferative disease
[18]. Longer follow-up of this treatment approach ina large phase II cohort has demonstrated a 3-year
EFS from diagnosis of consecutively enrolled patients
of 55% [19]. A second multiplecycle SCT study, per-
formed using 3 sequential SCT procedures, found
comparable results in terms of 3-year EFS (57%)
[17]. Based on these promising results, the current
open phase III COG trial, ANBL0532, is testing single
versus tandem transplantation as consolidation ther-
apy for high-risk NBL.BUSULFAN/MELPHALAN (BU/MEL) VERSUS
CARBOPLATIN/ETOPOSIDE/MELPHALAN
(CEM)
The combination of CEM is currently the effective
standard of care for NBL SCT in the United States,
having been used in COG A3973 as well as in both
arms of the COG ANBL0532 study. Recently, the
SIOPEN group has been testing the combination of
busulfan and melphalan for autologous SCT, compar-
ing this conditioning regimen to CEM. Although
these data have not yet been published, they were pre-
sented in a plenary session by Dr. Ruth Ladenstein at
the American Society of Clinical Oncology this year
[20]. Although only about one-third of enrolled pa-
tients actually underwent the randomization, the study
reports a statistically significant difference in outcome
between the Bu/Mel and CEM arms, with 3-year EFS
in the Bu/Mel being 48% compared with 33% with
CEM. Importantly, although rates of TRM were sim-
ilar in the 2 arms, Bu/Mel was far better tolerated, with
lower rates of all post-SCT toxicities with the single
exception of VOD/SOSS. The authors conclude that
this result establishes Bu/Mel as new standard of care
S94 Biol Blood Marrow Transplant 18:S92-S100, 2012S. A. Grupp et al.for NBL transplantation. At the same session, Dr. Julie
Park then provided a discussion of the study, contrast-
ing it with recent U.S. data. Although the groups of
high-risk NBL undergoing SCT in COG and
SIOPEN studies are not exactly congruent (largely
because of criteria for required response), it appears
that 3-year EFS from transplantation in patients
receiving CEM who did not subsequently receive im-
munotherapy is 46%, comparable to the SIOPEN
Bu/Mel result.
Of course, this raises the key question of whether
Bu/Mel would or will perform better in the U.S. con-
text, after the induction regimen most commonly in
the U.S. (a modification of the Sloan-Kettering N6
regimen). There is the possibility that there was a neg-
ative interaction between the SIOPEN Rapid COJEC
induction and CEM, although there is no obvious hy-
pothesis about why this should be the case. This would
potentially account for the lower results observed in
the CEM arm. At the same time, even similar perfor-
mance between Bu/Mel and CEM after N6 induction
would potentially be a win, given the reported lower
acute toxicities of the Bu/Mel conditioning regimen.
Another consideration is the issue of toxicities associ-
ated with local radiotherapy. Although a standard
dose of 2160 cGy and an abdominal field is well toler-
ated after Bu/Mel, there is unquestionably an interac-
tion between Bu/Mel and some uses of radiotherapy.
Whole-lung irradiation (almost never used in NBL)
is absolutely contraindicated after Bu/Mel because of
a very high risk of pulmonary fibrosis. An unknown
is how a limited field in a patient with thoracic NBL
would be tolerated—it appears that such patients
may have been taken off the SIOPEN study to receive
a CEM transplant, although the published report will
further clarify this. Also unknown is whether the toxic-
ity of local radiotherapy will be augmented in patients
who receive involved-field boosts up to 3600 cGy after
Bu/Mel, or even if such boosts, which are currently be-
ing tested in COG ANBL0532, are advisable. The ap-
proach being taken by the COG is to move with
caution. Bu/Mel will be piloted within COG for
high-risk NBL patients after a U.S.-style induction,
which will give us an initial sense for potential toxic-
ities and interactions. At the same time, the next U.S.
phase III study is being designed with the assumption
that Bu/Mel may indeed be used as the conditioning
regimen, once these issues are worked out.TUMOR CELL PURGING
In addition to increasing dose intensity, graft ma-
nipulation has been used to attempt to improve sur-
vival following autologous SCT in NBL. The most
researched manipulation in the context of NBL has
been purging of malignant cells before the infusionof the hematopoietic stem cell product. Early research
suggested that clonogenic tumor cells can be infused
with a hematopoietic stem cell graft, and that these
cells can result in relapse of the malignancy [21].
This led to trials addressing the question of whether
purging stem cell products of NBL cells could further
improve posttransplantation overall survival (OS) and
disease-free survival. The most widely used technique
in NBL has been antitumor monoclonal antibodies
followed by a magnetic depletion step [22,23],
although CD34 selection has also been tested [24]. Al-
though the evidence suggests that purging of bone
marrow may be important, PBSCs are less likely to
contain tumor cells than bone marrow, and no study
to date has shown that purging itself improves
outcome. This was borne out in COG A3973, which
was a phase III, randomized comparison of purged ver-
sus unpurged PBSC given in the context of autologous
SCT for high-risk NBL. Data from this trial presented
at ASCO IN 2008 [25] showed no advantage for pa-
tients receiving a purged PBSC. The 2-year EFS was
51% in the unpurged group and 47% in the purged
group (P 5 .47). The overall estimated 3-year EFS
was 40%. The lesson from these data may be that the
key to success is purging the tumor in the patient,
rather than the PBSC product.IMPACTOF BIOMARKERS ON NBLTHERAPY
The International NBL Risk Group (INRG) stag-
ing system’s risk stratification criteria for NBL are
based on clinical and biologic factors, including stage,
age at diagnosis, MYCN gene amplification status,
DNA index, copy number aberrations at chromosome
11q, and histology [26]. This approach has been most
successful in identifying those with low and intermedi-
ate risk who have.90% OS after receiving only mod-
erate intensity chemotherapy [27,28]. Although
treatment for children identified with high-risk NBL
has improved over the past 20 years, only 45% of these
patients become long-term, disease-free survivors
[4,14,19,29-33]. The majority of failures occur
within 2 years of diagnosis, and survival remains
poor among patients with disease progression
[32,34,35]. Improvement in survival for this high-risk
group necessitates development of effective new ther-
apies that target biologically risk-stratified subgroups
of patients and development of effective biomarker as-
says that provide prognostic information at the time of
diagnosis and during the course of therapy. This ap-
proach has been successfully implemented in patients
with acute lymphocytic leukemia, where risk-based as-
signment using clinical and genetic markers at diagno-
sis are further refined based on minimal residual
disease (MRD) evaluation of blood and bone marrow
early in the course of therapy.
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There already is precedent for defining risk for all
stages of NBL (local, regional, metastatic) based upon
molecular biologic aberrations in primary tumors.
The use of MYCN gene amplification to predict
outcome is a paradigm for this [36]. Chromosomal
losses such as 1p and 11q also provide additional prog-
nostic information [37-39], and additional studies
have demonstrated importance of chromosome 17
[40,41]. Several genomic and gene expression
profiling studies of NBL have also reported
associations with patient outcomes [39,42-46]. These
studies provide insight into the clinical heterogeneity
of NBL and have been most successful in predicting
poor outcome for patients classified as low or
intermediate risk as defined by INRG classification.
A study focused primarily on metastatic tumors
lacking MYCN gene amplification was the first to
demonstrate a prognostic signature for patients with
the same stage of disease (stage 4) based on RNA
profiling [47]. A 55-gene signature predicted the
likelihood of progression-free survival with \20%
error rate for patients over 12 or 18 months of age at
diagnosis. Surprisingly in that study, the microarray
signature showed that high expression of the immuno-
globulin kappa gene was predictive of poor outcome.
Gene ontology and gene set enrichment analysis also
identified antigen-binding genes and CCR5 and
CXCR4 macrophage signaling pathway as being
associated with the microarray-based high-risk group.
Inclusion of inflammation-related markers into a clini-
cally applicable 14-gene assay using TaqMan Low
Density Array has demonstrated the clinical signifi-
cance of expression of inflammation-related genes in
this high-risk group of patients (unpublished data).
This clinical assay has now been validated in 2
independent cohort of samples providing a high- and
ultrahigh-risk subgroup of patients with metastatic
MYCNnonamplified tumors. These data demonstrate
that expression profiling of primary tumors at diagno-
sis can provide clinically relevant prognostic informa-
tion for high-risk NBL patients.NBL PROGNOSTIC MARKERS DURING
THERAPY
Advances in molecular technologies have also
fueled research into discovery of gene-based assays
for detections of rare tumor cells that serve as surrogate
markers for tumor burden during therapy. Evaluations
are performed using specimens from bone marrow,
the most common site of disease recurrence [14,32].
The low sensitivity of morphologic assessment
initially prompted development of immunocytology,
which uses 4 different monoclonal antibodies to
identify tumor cells. Bone marrow and blood werefound to be positive for tumor cells in 81% and
58% of stage 4 patients respectively at diagnosis
by immunocytology, and quantifying tumor cells
throughout induction therapy provided independent
prognostic information [48]. Subsequently, reverse
transcription polymerase chain reaction (RT-PCR)
assays reportedly detect infrequent tumor cells and
predict outcome [49-53]. RNA expression of NBL-
specific genes including TH, GD2, and PHOX2b
have been frequently used in quantifying NBL cells
in the bone marrow. The selection of genes and
design of primers for such markers requires careful
evaluation to minimize false positives in normal bone
marrow samples. The heterogeneity in biology of
NBL is also evident in these studies, as multigene
detection assays have been shown to have superior
sensitivity and specificity for detection of MRD than
any 1 single gene. In our own ongoing research, we
have used data from microarray analyses of over 150
high-risk NBLs, normal neuronal tissues, and bone
marrow samples to develop a 5-gene RT-PCR detec-
tion assay that includes TH, PHOX2b, CHGA,
DCX, and DDC with high sensitivity and specificity.
In general, the limit of sensitivity ofMRD tests is as fol-
lows: morphology, 1 tumor cell among 100 normal
cells (1%); immunocytology, 1 tumor cell among
100,000-200,000 normal cells; RT-PCR, 1 NBL cell
among 500,000-1,000,000 bone marrow cells. Using
RT-PCR MRD assessment, 10% of patients with
metastatic disease have no detectable tumor cells in
bonemarrow at diagnosis as compared with 20% using
immunocytology [48,54]. Seeger et al. [48] reported
29% of patients had identifiable tumor cells at the
end of 12 weeks of therapy using immunoctology,
whereas Stutterheim et al. [54] showed that 71% have
detectable disease using RT-PCR 2 to 4 months after
the start of therapy. The latter group have also shown
that 11 of 38 (29%) of patients had early clearance of
tumor cells at 3 months after diagnosis and was associ-
ated with favorable outcome (5-year OS 62%6 15.0%
versus 19% 6 8%; P 5 .009). Analysis of peripheral
blood stem cells from 238 patients, which were ob-
tained 8 to 12 weeks after diagnosis, demonstrated
that 49.6% had detectible tumor cells using the
5-gene RT-PCR MRD signature (unpublished data).
Detection of tumor cells was associated with a signifi-
cantly worse EFS (35.0% 6 4.6% versus 50.4 6
4.6%; P5 .014) at 3 years after diagnosis than nonde-
tection. Analysis of bone marrow obtained at the end
of induction was reported to be MRD positive in
12 of the 29 samples (41%), whereas only 5 of
these samples were also positive by immunocytology
[54]. All patients with MRD-positive bone marrow
died of progressive disease. Further studies should pro-
vide additional clinical information about the
robustness and validity of these assays during induction
period.
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Figure 1. Chemical structure of 131I-metaiodobenzylguanidine and
norepinephrine.
Figure 2. 123I-mIBG scintigraphy. Extensive mIBG avid disease in
cranium, orbits, sinofacial region, bilateral humeri, and sternum.
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introduced new possibilities for monitoring tumor
response to therapy.Tumor-specific translocation sites
can now be identified using next-generation sequenc-
ing technologies that allow design of patient-specific
PCR primers for quantification of circulating tumor
DNA. However, it is unclear if these translocation
events are preserved during the clonal evolution of
tumors aftermultiple rounds of chemotherapy. Finally,
ongoing analyses combining strategies that monitor
response to therapy such as RT-PCR MRD or MIBG
imaging strategies [55,56] should allow identification
of subgroups of rapid-responders among patients
who are classified as high-risk or ultrahigh-risk using
RNA signatures of pretherapy samples. These strate-
gies would facilitate appropriate selection of patients
for autologous hematopoietic SCT.RADIOLABELED
METAIODOBENZYLGUANIDINE (mIBG) AND
AUTOTRANSPLANT
NBL is a malignancy of sympathetic nervous
system origin, one that has the ability to concentrate,
store, and secrete catecholamine metabolites. In
.90% of cases, increased levels of urinary catechol-
amines, including dopamine, homovanillic acid, and/
or vanillymandelic acid, are present at diagnosis.
mIBG is a norepinephrine analogue initially devel-
oped at the University of Michigan in the 1970s for
adrenal imaging [57] (Figures 1 and 2). Similar to
norepinephrine, mIBG has the ability to concentrate
in neural crest tissues and NBL via cell surface
norepinephrine transport channels. The ability to
radiolabel mIBG with various iodine isotopes,
including I-131 or I-123, led to its subsequent use in
NBL imaging in the early 1980s [58-62]. Both
131I-mIBG and 123I-mIBG are currently licensed for
scintigraphic imaging of NBL, with 131I-mIBG
currently in use as a therapeutic modality. Thepotential impact of 131I-mIBG in NBL therapy is
enhanced by its ability to concentrate within tumors
with diverse presentations and biology. mIBG uptake
is well described in both primary tumor sites and
metastases, including soft tissue, bone marrow, and
bony lesions. mIBG concentrates in tumors with
favorable or unfavorable histologic patterns, amplified
or nonamplified MYCN oncogene expression, and
low-stage as well as advanced-stage disease [60,62-64].
These features make 131I-mIBG an attractive therapy
option for patients with high-risk NBL.131I-mIBG THERAPY: GENERAL OVERVIEW
Over the past 2 decades, 131I-mIBG therapy has
focused on palliation for patients with refractory
disease, specifically targeting those patients who fail
induction or develop progressive disease posttrans-
plantation. The benefits of 131I-mIBG in this disease
setting have now been established, and current proto-
cols are investigating its role with adjuvant chemother-
apy, biologic response modifiers, or in combination
with transplant conditioning regimen. A dose-
dependent response has been noted, with dose escala-
tion from 8 to 21 mCi/kg associated with increasing
levels of tumor response [65]. When given as single
agent therapy, response rates have ranged from 10%
to 55% for patients with end-stage or refractory dis-
ease [66]. In a large case series of 164 patients, re-
sponses were seen in 45% of patients with disease
isolated to the bone and/or bone marrow, and 50%
for patients with isolated soft tissue involvement [65].
Improved response rates were also seen in patients
.12 years old (55% response rates) and those having
Figure 3. Phase I study of 131I-mIBGwithCEMchemotherapy and autol-
ogous stemcell rescue for patientswith refractory neuroblastoma. Event-
free and overall survival. Matthay KK, et al. J Clin Oncol. 2006;24:500-506.
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ported toxicities have been mild, including infusion re-
lated nausea and vomiting, myelosuppression, and the
potential for hypothyroidism [65]. The primary toxic-
ity remains hematologic, with stem cell rescue
required in patients receiving .15 mCi/kg of
131I-mIBG [66]. For current North American trials,
131I-mIBG therapy still requires an adequate number
of stem cells to be collected and cryopreserved in ad-
vance of therapy. Late complications of 131I-mIBG
therapy have been rare, with hypothyroidism (10%),
adrenal insufficiency (\5%), and secondary
malignancies (\5%) all reported [66].131I-mIBG THERAPY: ROLE IN THE
AUTOLOGOUS TRANSPLANT SETTING
As noted above, the ability to combine 131I-mIBG
with chemotherapy, radiosensitizers, or biologic re-
sponse modifiers has grown dramatically in the past
decade. A pilot study in the 1990s at the University
of Michigan, incorporating 131I-mIBG directly into
the transplant conditioning regimen for 12 patients
who had failed induction therapy, demonstrated feasi-
bility and efficacy [67]. All 12 patients received 12
mCi/kg of 131I-mIBG given on day221 pretransplan-
tation, followed by CEM administered days 27 to 24
pretransplantation. Responses were seen in 5 of the 8
patients with metastatic disease and 3 of 4 patients
with localized disease. A subsequent phase I trial per-
formed by the New Approaches to Neuroblastoma
Therapy (NANT consortium) identified 12 mCi/kg
as the MTD dose for 131I-mIBG, when given in com-
bination with a CEM conditioning regimen for pa-
tients with refractory disease [35]. Six of 22 patients
(27%) had a complete or partial response to therapy,
with estimated 3-year EFS 0.31 1 0.10 and OS
0.58 1 0.10 (Figure 3). The use of radioation labeled
mIBG in the conditioning regimen did not appear to
affect hematologic recovery posttransplant. Engraft-ment was brisk in both studies, with a median time
to neutrophil recovery (.500/mL) 10 days and platelet
recovery 26 to 28 days for the 2 studies. Primary toxic-
ities of the regimen included grade 3-4 oral mucositis,
febrile neutropenia, and hepatic toxicity, with hepatic
veno-occlusive disease (VOD) seen in 6 of the 22 pa-
tients treated in the NANT study. The high incidence
of VOD in this study stands in contrast to single-agent
131I-mIBG therapy studies, in which hepatic toxicity is
uncommon (\5%), and in contrast to the Michigan
study, in which no VOD was noted in the 12 patients
treated. Given the above phase I results, a number of
phase I/II studies have now been completed, both
within North America and Europe, the majority focus-
ing on patients with mIBG avid, nonresponsive, or
progressive disease [68,69]. The combination of
irinotecan, vincristine, plus 131I-mIBG appears to
be an attractive option to the 131I-mIBG-CEM
transplant regimen, with a phase I study recently
completed by the NANT consortium [70]. Although
myeloablative at the defined maximal tolerated dose
of 18 mCi/kg 131I-mIBG, the regimen is associated
with significantly less epithelial injury than 131I-
mIBG-CEM, with minimal oral mucosal and hepatic
toxicity reported. Based upon the safety profile and po-
tential efficacy of this regimen, the combination of iri-
notecan, vincristine, and 131I-mIBG with stem cell
rescue is being considered for a randomized, phase
III trial within the COG for the treatment of patients
with high-risk NBL in first response.PROGNOSTIC IMPACTOF
PRETRANSPLANTATION mIBG SCANS
Over the past 15 years, a semiquantitative mIBG
scoring system (Curie scoring system) has been
developed to estimate the extent and severity of mIBG
avid disease [71-73]. Such assessments, when
performed during or following induction therapy,
have been predictive of subsequent tumor response
and progression-free survival [72-76]. The Curie
scoring system is based upon the extent of mIBG
uptake in multiple anatomical regions, with numeric
scores assigned to the degree of involvement in each
region. The scores from each individual region are
subsequently summated to determine a composite
score [71,72]. Both composite and ‘‘relative’’ scores
(obtained by dividing the absolute score at each time
point by the corresponding pretreatment score) have
been extremely reliable in predicting response [72,76].
In particular, the presence of a .75% decline in Curie
score following 4 cycles of induction therapy has been
associated with improved EFS and OS. The COG is
currently conducting a mIBG scan review of nearly
300 patients treated on a homogenous high-risk NBL
protocol, COG A3973 [77]. Curie scores are being de-
termined from mIBG scans obtained at the time of
S98 Biol Blood Marrow Transplant 18:S92-S100, 2012S. A. Grupp et al.diagnosis, postinduction therapy (pretransplantation),
posttransplantation, and postbiotherapy. Initial analysis
indicates that pretransplantation Curie scores will have
a significant impact in determining subsequent post-
transplantation EFS [77]. Ultimately, the Curie scoring
method may prove to be a valuable tool in the decision-
making process for transplantation, both in terms of
determining the optimal timing of transplantation and
intensity of the transplantation regimen. Patients with
high Curie scores pretransplantation could even be
considered for alternative transplantation regimen,
including options that incorporate mIBG therapy
directly into the transplantation process.ACKNOWLEDGMENTS
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